



Corrections: Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 [IFRS]

March 7, 2023

Kao Corporation (Ticker Code:4452) makes certain corrections to "Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 [IFRS]" released on February 2, 2023 and revised on February 10, 2023. The corrections are underlined as shown on the following pages.

Content of the Revision

The section entitled "1. Segment Information (2) Sales and results of reportable segments" in the "Notes to Consolidated Financial Statements" on page 22, "Capital expenditure" has been corrected.

For further information, please contact:

Mitsuhiro Watanabe Vice President Investor Relations E-mail: ir@kao.co.jp



1. Segment Information

(2) Sales and results of reportable segments

[Correction]

									(Millions of yen)
Fiscal year ended	Reportable Segments								
December 31, 2022	Consumer Products Business								
	Hygiene and Living Care Business	Health and Beauty Care Business	Life Care Business	Cosmetics Business	Subtotal	Chemical Business	Total	Reconciliations ¹	Consolidated
Net sales									
Sales to customers	516,548	369,549	55,734	251,472	1,193,303	357,756	1,551,059	-	1,551,059
Intersegment sales and transfers ²		-	-	-	-	44,745	44,745	(44,745)	-
Total net sales	516,548	369,549	55,734	251,472	1,193,303	402,501	1,595,804	(44,745)	1,551,059
Operating income (loss)	30,674	34,596	(15)	14,086	79,341	29,516	108,857	1,214	110,071
% of net sales	5.9	9.4	- '	5.6	6.6	7.3	-	-	7.1
Financial income									5,650
Financial expenses									(2,418)
Share of profit in investments accounted for using									2,545
the equity method Income before income taxes									115,848
Depreciation and amortization	35,106	18,800	3,406	14,469	71,781	16,918	88,699	1,039	89,738
Impairment loss	-	-	-	34	34	-	34	-	34
Capital expenditure ³	40,011	22,425	2,356	12,370	77,162	17,022	94,184	383	94,567

Notes:

- 1. The operating income (loss) reconciliation of 1,214 million yen includes corporate expenses not allocated to reportable segments, as well as elimination of intersegment inventory transactions.
- 2. Intersegment sales and transfers are mainly calculated based on market price and manufacturing cost.
- 3. Capital expenditures include investments in property, plant and equipment, right-of-use assets and intangible assets.

[Original]

									(Millions of yen)
Fiscal year ended	Reportable Segments								
December 31, 2022	Consumer Products Business								
	Hygiene and Living Care Business	Health and Beauty Care Business	Life Care Business	Cosmetics Business	Subtotal	Chemical Business	Total	Reconciliations ¹	Consolidated
Net sales									
Sales to customers	516,548	369,549	55,734	251,472	1,193,303	357,756	1,551,059	-	1,551,059
Intersegment sales and transfers ²	<u> </u>		<u>-</u>	<u> </u>	<u> </u>	44,745	44,745	(44,745)	
Total net sales	516,548	369,549	55,734	251,472	1,193,303	402,501	1,595,804	(44,745)	1,551,059
Operating income (loss)	30,674	34,596	(15)	14,086	79,341	29,516	108,857	1,214	110,071
% of net sales	5.9	9.4	-	5.6	6.6	7.3			7.1
Financial income									5,650
Financial expenses									(2,418)
Share of profit in investments accounted for using the equity method									2,545
Income before income taxes									115,848
Depreciation and amortization	35,106	18,800	3,406	14,469	71,781	16,918	88,699	1,039	89,738
Impairment loss	-	-	-	34	34	-	34	-	34
Capital expenditure ³	39,234	22,003	2,189	12,143	75,569	16,932	92,501	240	92,741

Notes

- 1. The operating income (loss) reconciliation of 1,214 million yen includes corporate expenses not allocated to reportable segments, as well as elimination of intersegment inventory transactions.
- 2. Intersegment sales and transfers are mainly calculated based on market price and manufacturing cost.
- 3. Capital expenditures include investments in property, plant and equipment, right-of-use assets and intangible assets.